NLRP3 and cryopyrin-associated periodic syndrome: Tranilast (200 mg/kg) has been documented to increase body weight and survival and to produce demonstrable therapeutic benefits in murine models of NLRP3-induced gouty arthritis, MSU-induced peritonitis, and cryopyrin-associated periodic syndromes (CAPS).